November 23, 2023
Dr. Trier with Prof. Zeng, a renowned myopia researcher from China, at the EVER 2023 conference in València, Spain, October 26-28
At the EVER meeting in València, Spain, Dr. Klaus Trier was invited to talk at the myopia control session. Dr. Trier presented the latest analysis of data from 757 myopic children demonstrating high efficacy of 7-MX. For example, in children aged 7-10 and with less than 4 diopter myopia, the estimated effect of taking 2.5 of the current tablet per day is 1.71 diopter less myopia progression and 0.64 mm less eye elongation over six years.
In the ensuing debate, Dr. Trier stated that after several clinical trials have failed to show significant effect of low-concentration atropine eyedrops, 7-MX may be the only effective pharmaceutical for myopia control in current use.
The efficacy of optical devices designed to control myopia progression is insufficient, especially for children aged 7-10 years who are at risk of developing high myopia (more than 6 diopters), and it is therefore essential to develop an effective pharmaceutical myopia control treatment. 7-MX has been shown to be effective, safe and without side-effects and is therefore a good candidate.
April 05, 2023
TheiaLife signs Agreement with LifeSci Consulting for transaction advisory services for strategic partnering initiatives.
January 31, 2023
Featured in a second peer-reviewed publication in the International Journal of Ophthalmology. Read our latest article on the “Role of 7-methylxanthine in myopia prevention and control: a mini-review”
August 18, 2022
Exciting news! Theialife is pleased to announce the first-in-class drug for Myopia control in Children – an unmet need. Please find the article released in the coveted British Journal of Ophthalmology.